Slide 1

Presented By Susan Chang at 2014 ASCO Annual Meeting

Imaging assessment in Neuro-Oncology

Presented By Susan Chang at 2014 ASCO Annual Meeting

Limitation: Early Pseudo-Progression <br />after radiochemotherapy<br />

Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 4

Presented By Susan Chang at 2014 ASCO Annual Meeting

Limitation- Determination of enhancing and non- enhancing tumor burden post antiangiogenic treatment

Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 6

Presented By Susan Chang at 2014 ASCO Annual Meeting

# 2007 Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab- Huang et al

Presented By Susan Chang at 2014 ASCO Annual Meeting

Assessment of RANO

Presented By Susan Chang at 2014 ASCO Annual Meeting

RANO-Endpoints and Trial Design

Presented By Susan Chang at 2014 ASCO Annual Meeting

# 2005- Final Results of APG101_CD_002: <br />APG101 + Reirradiation versus Reirradiation in the Treatment of Patients with Progressive Glioblastoma: Platten et al

Presented By Susan Chang at 2014 ASCO Annual Meeting

Results

Presented By Susan Chang at 2014 ASCO Annual Meeting

APG101_CD_002: Novel Biomarker for OS

Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 13

Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 14

Presented By Susan Chang at 2014 ASCO Annual Meeting

Slide 15

Presented By Susan Chang at 2014 ASCO Annual Meeting

Results for ICT-107 Ph II

Presented By Susan Chang at 2014 ASCO Annual Meeting

Authors conclusions/Comments

Presented By Susan Chang at 2014 ASCO Annual Meeting

Authors conclusions/Comments

Presented By Susan Chang at 2014 ASCO Annual Meeting

What “success” in a phase II trial warrants phase III evaluation?

Presented By Susan Chang at 2014 ASCO Annual Meeting

Future RANO efforts

Presented By Susan Chang at 2014 ASCO Annual Meeting

Acknowledgements

Presented By Susan Chang at 2014 ASCO Annual Meeting